How Can A Closed CAR-T Manufacturing Process De-Risk Your Process, Reduce Costs And Improve Efficiency?
Source: OmniaBio
In a previous post we introduced chimeric antigen receptor T-cell (CAR-T) therapy - a new form of cancer therapy based on genetically reprogramming the body’s immune system that has been described as a “breakthrough” and “revolutionary” by the medical and scientific communities.
This post will explore how developing customized solutions for system closure can solve a key technical bottleneck and advance CAR-T manufacturing.
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
OmniaBio
This website uses cookies to ensure you get the best experience on our website. Learn more